An intermediate telephone survey after two intervention components (week 25) was used to assess all participants' behaviors and determinants to gather the most recent information for the computer-tailored intervention and assess the intermediate effects of the interventions.
Half of the participants in the TPC, TMI, and combined groups received their pedometer before the third intervention component (week 29); the remainder received the pedometer after the last follow-up.
CHWs in Brazil receive an 8 week residential course that includes curative, preventive and promotive components, 4 weeks of fieldwork followed by on-going training sessions [ 5].
The study design and timeline is depicted in Figure 2. Participants' behaviors and determinants were assessed by an intermediate telephone survey after two intervention components, 25 weeks after returning the baseline questionnaire, to gather the most recent information for the computer tailoring intervention.
No significant difference between these groups was seen for other ACR components before week 68 (total swollen joints) or week 92 (patient global assessment and physician global assessment), after which time the combination group showed better responses (p<0.05).
Ms. Schmaler said 24 components each week submit such reports, compiling references to hundreds of issues.
As shown in Figure 5, treatment with IL-2 or anti-IL-2 alone prior to transplantation did not alter the percentages of BrdU-positive cells in both CD4+ and CD8+ components one week after transplantation (BrdU+ in anti-IL-2 group: CD4: 40±2% vs. 41±3%, CD8: 42±3% vs. 43±4%; and BrdU+ in IL-2 group: CD4: 43±4% vs. 41±3%, CD8: 45±5% vs. 43±4%, all P>0.05).
For patients who did not meet the treatment failure criteria, the missing ASAS components at week 104 were replaced with the last non-missing value.
Patients treated with certolizumab pegol experienced statistically significant improvements in all ACR components at week 24 vs placebo (p⩽0.05) (table 2, fig 3).
There was a significant difference in the overall score between the two time points, which included the inflammatory score component (2 weeks vs. 7 weeks: 17.8 ± 1.5 vs 12.3 ± 0.9 p=0.009, n=8-9, Fig. 5a).
